Dkt.#638-A

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : CHEUNG, Nai-Kong V.

U.S. Serial No.: 09/982,645, claiming benefit of U.S. Serial No. 60/241,344, filed on October 18, 2000

Filing Date : October 18 2001 Group Art Unit: 1645

For : USES OF MONOCLONAL ANTIBODY 8H9

141-07 20th Avenue, Suite 604
Whitestone, NY 11357

January 23, 2002

Honorable Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

INFORMATION DISCLOSURE STATEMENT

In accordance with their duty of disclosure under 37 C.F.R. § 1.56, Applicant would like to direct the Examiner's attention to the following references which are listed on Form PTO-1449 (Exhibit A) and are attached hereto as Exhibits 1 through 175, respectively:

1. Cheung, N. K. V., Kushner, B. H., Cheung, I. Y., Canete, A., Gerald, W., Liu, C., Finn, R., Yeh, S. J., Larson, S. M. Anti-GD2 antibody treatment of minimal residual stage 4 neuroblastoma diagnosed at more than 1 year of age. J. Clin. Oncol., 16:3053-3060, 1998. (Exhibit 1)

2. Yu, A., Uttenreuther-Fischer, M., Huang, C.-S., Tsui, C., Gillies, S., Reisfeld, R., Kung, F. Phase I trial of

a human-mouse chimeric anti-disialoganglioside monoclonal antibody ch14.18 in patients with refractory neuroblastoma and osteosarcoma. J. Clin. Oncol., 16:2169-2180, 1998. (Exhibit 2)

3. Jurcic, J. G., Caron, P. C., Miller, W. H., Yao, T. J., Maslak, P., Finn, R. D., Larson, S. M., Warrell, R. P. J., Scheinberg, D. A. Sequential targeted therapy for acute promyelocytic leukemia with all-trans retinoic acid and anti-CD33 monoclonal antibody M195. Leuk., 9:244-248, 1995. (Exhibit 3)

4. Czuczman, M. S., Grilo-Lopez, A. J., White, C. A., Saleh, M., Gordon, L., LoBuglio, A. F., Jonas, C., Klippenstein, D., Dallaire, B., Varns, C. Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy. J. Clin. Oncol., 17:268-276, 1999. (Exhibit 4)

5. Garin-Chesa, P., Fellinger, E. J., Huvos, A. G., Beresford, H. R., Melamed, M. R., Triche, T. J., Rettig, W. J. Immunohistochemical analysis of neural cell adhesion molecules. Differential expressionin small round cell tumors of childhood and adolescence. Am. J. Pathol., 139:275-286, 1991. (Exhibit 5)

6. Ritter, G., Livingston, P. O. Ganglioside antigens expressed by human cancer cells. Semin. Cancer. Biol., 2:401-409, 1991. (Exhibit 6)

7. Ylagan, Quinn, L. R. B: CD44 expression in astrocytic tumors. Modern Pathology, 10:1239-1246, 1997. (Exhibit 7)

8. Kuan, C. T., Reist, C. J., Foulon, C. F., Lorimer, I. A., Archer, G., Pegram, C. N., Pastan, I., Zalutsky, M. R., Bigner, D. D. 125I-labeled anti-epidermal growth factor receptor vIII single-chain Fv exhibits specific and high-level targeting of glioma xenografts. Clin. Can. Res., 5:1539-1549, 1999. (Exhibit 8)

9. Richardson, R. B., Davies, A. G., Bourne, S. P., Staddon, G. E., Jones, D. H., Kemshead, J. T., Coakham, H. B. Radioimmunolocalization of human brain tumors. Biodistribution of radiolabelled monoclonal antibody UJ13A. Eur J Nucl Med, 12:313-320, 1986. (Exhibit 9)

10. Papanastassiou, V., Pizer, B. L., Coakham, H. B., Bullimore, J., Zananiri, A., Kemshead, J. T. Treatment of recurrent and cystic malignant gliomas by a single intracavitary injection of 131I-monoclonal antibody: Feasibility, pharmacokinetics and dosimetry. Br. J. Cancer, 67:144-151, 1993. (Exhibit 10)

11. Celis, E., Tsai, V., Crimi, C., Demars, R., Wentworth, P. A., Chesnut, R. W., Grey, H. M., Sette, A., Serra, H. M. Induction of anti-tumor cytotoxic T lymphocytes in normal humans using primary cultures and synthetic peptide epitopes. Proc. Natl. Acad. Sci. USA, 91:2105-2109, 1994. (Exhibit 11)

12. Riva, P., Frnceschi, G., Frattarelli, M., Riva, N., Guiduci, G., Cremonini, A. M., Giulaiani, G., Casi, M., Gentile, R., Jekunen, A., Kairemo, K. J. 131I radioconjugated antibodies for the locoregional radioimmunotherapy of high-grade malignant glioma- phase I and II study. Acta Oncol, 38:351-359, 1999. (Exhibit 12)

13. Heiner, J., Miraldi, F. D., Kallick, S., Makley, J., Smith-Mensah, W. H., Neely, J., Cheung, N. K. V. Localization of GD2 specific monoclonal antibody in human osteogenic sarcoma. Cancer Res., 47:5377-5381, 1987. (Exhibit 13)

14. Spendlove, I., James, L. L., Carmichael, J., Durrant, L. G. Decay accelerating factor (CD55): a target for cancer vaccines? Cancer Res., 59:2282-2286, 1999. (Exhibit 14)

15. Weidner, N., Tjoe, J. Immunohistochemical profile of monoclonal antibody O13 that recognizes glycoprotein 930/32MIC2 and is useful in diagnosing ewing's sarcoma

and peripheral neuroepithelioma. American Journal of Surgical Pathology, 18:486-494, 1994. (Exhibit 15)

16. Hatzubai, A., Maloney, D. G., Levy, R. The use of a monoclonal anti-idiotype antibody to study the biology of human B-cell lymphoma. J. Immunol., 126:2397-2402, 1981. (Exhibit 16)

17. Cheung, N. K., Saarinen, U., Neely, J., Landmeier, B., Donovan, D., Coccia, P. Monoclonal antibodies to a glycolipid antigen on human neuroblastoma cells. Cancer Res., 45:2642-2649, 1985. (Exhibit 17)

18. Kramer, K., Gerald, W., LeSauteur, L., Saragovi, H. U., Cheung, N. K. V. Prognostic value of TrkA protein detection my monoclonal antibody 5C3 in Neuroblastoma. Clin. Can. Res., 2:1361-1367, 1996. (Exhibit 18)

19. Hecht, T. T., Longo, D. L., Cossman, J., Bolen, J. B., Hsu, S.-M., Israel, M., Fisher, R. I. Production and characterization of a monoclonal antibody that binds reed-sternberg cells. J. Immunol., 134:4231-4236, 1985. (Exhibit 19)

20. Seeger, R. C., Danon, Y. L., Rayner, S. A., Hoover, F. Definition of a Thy-1 determinant on human neuroblastoma, glioma, sarcoma, and teratoma cells with a monoclonal antibody. J. Immunol., 128:983-989, 1982. (Exhibit 20)

21. Kaaijk, P., Troost, D., Morsink, F., Keehnen, R. M., Leenstra, S., Bosch, D. A., Pals, S. T. Expression of CD44 splice variants in human primary brain tumors. Journal of Neuro- Oncology, 26:185-190, 1995. (Exhibit 21)

22. Wikstrand, C. J., Longee, D. C., McLendon, R. E., Fuller, G. N., Friedman, H. S., Fredman, P., Svennerholm, L., Bigner, D. D. Lactotetraose series ganglioside 3',6'-isoLD1 in tumors of central nervous and other systems in vitro and in vivo. Cancer Res., 53:120-126, 1993. (Exhibit 22)

23. Pappo, A., Shapiro, D. N., Crist, W. M. Rhabdomyosarcoma: biology and treatment. Pediatr. Clin. North Am., 44:953-972, 1997. (Exhibit 23)

24. Fujisawa, T., Xu, Z. J., Reynolds, C. P., Schultz, G., Bosslet, I. V., Seeger, R. C. A monoclonal antibody with selective immunoreactivity for neuroblastoma and rhabdomyosarcoma. Proc. Am. Assoc. Cancer Res., 30:345, 1989. (Exhibit 24)

25. Wikstrand, C. J., Hale, L. P., Batra, S. K., Hill, M. L., Humphrey, P. A., Kurpad, S. N., McLendon, R. E., Moscatello, D., Pegram, C. N., Reist, C. J., et al. Monoclonal Antibodies against EGFRvIII are Tumor Specific and React with Breast and Lung Carcinomas and

Malignant Gliomas. Cancer Res., 55:3140-48, 1995. (Exhibit 25)

26. Kishima, H., Shimizu, K., Tamura, K., Miyao, Y., Mabuchi, E., Tominage, E., Matsuzaki, J., Hayakawa, T. Monoclonal antibody ONS-21 recognizes integrin a3 in gliomas and gliomas and medulloblastomas. Br. J. Cancer, 79:333-339, 1998. (Exhibit 26)

27. Moriuchi, S., Shimuzu, K., Miyao, Y., Hayakawa, T. Characterization of a new mouse monoclonal antibody (ONS-M21) reactive with both medulloblastomas and gliomas. Br. J. Cancer, 68:831-837, 1993. (Exhibit 27)

28. Kondo, S., Miyatake, S., Iwasaki, K., Oda, Y., Kikuchi, H., Zu, Y., Shomoto, M., Namba, Y. Human glioma-specific antigens detected by monoclonal antibodies. Neurosurgery, 30:506-511, 1992. (Exhibit 28)

29. Dastidar, S. G., Sharma, S. K. Monoclonal antibody against human glioblastoma multiforme (U-87Mg) immunoprecipitates a protein of monoclonal mass 38KDa and inhibits tumor growth in nude mice. J Neuroimmuno, 56:91-98, 1995. (Exhibit 29)

30. Mihara, Y., Matsukado, Y., Goto, S., Ushio, Y., Tokumitsu, S., Takahashi, K. Monoclonal antibody against ependymoma-derived cell line. Journal of Neuro-Oncology, 12:1-11, 1992. (Exhibit 30)

31. Daghighian, F., Pentlow, K. S., Larson, S. M., Graham, M. C., DiResta, G. R., Yeh, S. D., Macapinlac, H., Finn, R. D., Arbit, E., Cheung, N. K. Development of a method to measure kinetics of radiolabeled monoclonal antibody in human tumour with applications to microdosimetry: positron emission tomography studies of iodine-124 labeled 3F8 monoclonal antibody in glioma. Eur J Nucl Med, 20:402-409, 1993. (Exhibit 31)

32. Plate, K. H., Breier, G., Farell, C. L., Risau, W. Platelet derived growth factor b is induced during tumor development and upregulated during tumor progressing in endothelial cells in human gliomas. Lab. Invest., 67:529-534, 1992. (Exhibit 32)

33. Yang, H. S., Lieska, N., Glick, R., Shao, D., Pappas, G. D. Expression of 300-kilodalton intermediate filament-associated protein distinguishes human glioma cells from normal astrocytes. Proceedings of the National Academy of Sciences of the United States of America, 90:8534-8537, 1993. (Exhibit 33)

34. Koehler G, Milstein C: Continuous culture of fused cells secreting antibody of pre-defined specificity. Nature 256:495-496, 1975. (Exhibit 34)

35. Moffat R, Pinsky CM, Hammershaimb L, et al: Clinical utility of external immunoscintigraphy with the IMMU-4

technetium-99m Fab' antibody fragment in patients undergoing surgery for carcinoma of the colon and rectum:results of a pivotal, phase III trial. The Immunomedics Study Group. J Clin Oncol 14(8):2295-2305, 1996 (Exhibit 35)

36. Maloney DG, Grillo-Lopez AJ, Bodkin DJ, et al: IDEC-C2B8: Results of a phase I multiple-dose trial in patients with relapsed non-hodgkin's lymphoma. J Clin Oncol 15:3266-3274, 1997 (Exhibit 36)

37. Cobleigh MA, Vogel CL, Tripathy D, et al: Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 17:2639-2648, 1999 (Exhibit 37)

38. Meredith RF, Khazaeli MB, Plott WE: Phase II study of dual 131I-labeled monoclonal antibody therapy with interferon in patients with metastatic colorectal cancer. Clin Can Res 2:1811-1818, 1996 (Exhibit 38)

39. Yeh SD, Larson SM, Burch L, et al: Radioimmunodetection of neuroblastoma with iodine-131-3F8: Correlation with biopsy, iodine-131-Metaiodobenzylguanidine (MIBG) and standard diagnostic modalities. J Nucl Med 32:769-776, 1991 (Exhibit 39)

40. Wheldon TE, O'Donoghue JA, Barrett A, Michalowski AS: The curability of tumors of differing size by targeted radiotherapy using 131-I or 90-Y. Radiother Oncol 21:91-99, 1991 (Exhibit 40)

41. Wilder RB, DeNardo GL, DeNardo SJ: Radioimmunotherapy: recent results and future directions. J Clin Oncol 14:1383-1400, 1996 (Exhibit 41)

42. Zalutsky MR, McLendon RE, Garg PK, et al: Radioimmunotherapy of neoplastic meningitis in rats using an alpha-particle-emitting immunoconjugate. Cancer Res 54:4719-4725, 1994 (Exhibit 42)

43. McDevitt MR, Sgouros G, Finn RD, et al: Radioimmunotherapy with alpha-emitting nuclides. Eur J Nucl Med 25:1341-1351, 1998 (Exhibit 43)

44. DeNardo SJ, DeNardo GL, DeNardo DG, et al: Antibody phage libraries for the next generation of tumor targeting radioimmunotherapeutics. Clin Can Res 5:3213s-3218s, 1999 (Exhibit 44)

45. DeNardo SJ, DeNardo GL, Brush J, Carter P: Phage Library-derived human anti-TETA anti anti-DOTA ScFv for pretargeting RIT. Hybridoma 18:13-21, 1999 (Exhibit 45)

46. Eshhar Z, Waks T, Gross G, Schindler DG: Specific activation and targeting of cytotoxic lymphocytes

through chimeric single chains consisting of antibody-binding domains and the or zeta subunits of the immunoglobulin and T-cell receptors. Proc Natl Acad Sci USA 90:720-24, 1993 (Exhibit 46)

47. Altenschmidt U, Kahl R, Moritz D, et al: Cytolysis of tumor cells expressing the Neu/erbB-2, erbB-3, and erbB-4 receptors by genetically targeted naive T lymphocytes. Clin Can Res 2:1001-1008, 1996 (Exhibit 47)

48. Krause A, Guo HF, Tan C, et al: Antigen-dependent CD-28 signaling enhances survival and proliferation in genetically modified activated human primary T lymphocytes. J Exp Med 188:619-626, 1998 (Exhibit 48)

49. Price MR, Campbell DG, Robyn RA: Characteristics of the cell surface antigen p72, associated with a variety of human tumors and mitogen-stimulated T-lymnphoblasts. FEBS Letters 171:31-35, 1984 (Exhibit 49)

50. Gorlick R, Huvos AG, Heller G, et al: Expression of HER2/erbB-2 correlates with survival in osteosarcoma. J Clin Oncol 17:2781-2788, 1999 (Exhibit 50)

51. Cheung NK, Heller G, Kushner BH, et al: Detection of metastatic neuroblastoma in bone marrow: when is routine marrow histology insensitive? J Clin Oncol 15:2807-2817, 1997 (Exhibit 51)

52. Ghossein RA, Osman I, Bhattacharya S, et al: Detection of circulating prostatic tumor cells using immunobead reverse transcriptase polymerase chain reaction for prostatic specific membrane antigen mRNA. Diag Mol Path 8:59-65, 1999 (Exhibit 52)

53. Leung W, Chen AR, Klann RC, et al: Frequent detection of tumor cells in hematopoietic grafts in neuroblastoma and ewing's sarcoma. Bone Marrow Transpl 22:971-979, 1998 (Exhibit 53)

54. Mueller BM, Romerdahl CA, Gillies SD, Reisfeld RA: Enhancement of antibody-dependent cytotoxicity with a chimeric anti-GD2 antibody. J Immunol 144:1382-1386, 1990 (Exhibit 54)

55. Santos AD, Kashmiri VS, Horan PH, et al: Generation and characterization of a single gene-encoded single-chain-tetravalent antitumor antibody. Clin Can Res 5:3118s-3123s, 1999 (Exhibit 55)

56. Guo HF, Rivlin K, Dubel S, Cheung NKV: Recombinant anti-ganglioside GD2 scFv-streptavidin fusion protein for tumor pretargeting. Proc Am Assoc Cancer Res 37:469, 1996 (abstract) (Exhibit 56)

57. Fagnou C, Michon J, Peter M, et al: Presence of tumor cells in bone marrow but not in blood is associated with

adverse prognosis in patients with ewing's tumor. J Clin Oncol 16:1707-1711, 1998 (Exhibit 57)

58. Munn DH, Cheung NK: Interleukin-2 enhancement of monoclonal antibody-mediated cellular cytotoxicity (ADCC) against human melanoma. Cancer Res 47:6600-6605, 1987 (Exhibit 58)

59. Hank JA, Robinson RR, Surfus J, et al: Augmentation of antibody dependent cell mediated cytotoxicity following in vivo therapy with recombinant interleukin-2. Cancer Res 50:5234-5239, 1990 (Exhibit 59)

60. Kushner BH, Cheung NK: GM-CSF enhances 3F8 monoclonal antibody-dependent cellular cytotoxicity against human melanoma and neuroblastoma. Blood 73:1936-1941, 1989 (Exhibit 60)

61. Kushner BH, Cheung NKV: Absolute requirement of CD11/CD18 adhesion molecules, FcRII and phosphatidylinositol-linked FcRIII for monoclonal antibody-mediated neutrophil anti-human tumor cytotoxicity. Blood 79:1484-1490, 1992 (Exhibit 61)

62. Saarinen UM, Coccia PF, Gerson SL, et al: Eradication of neuroblastoma cells in vitro by monoclonal antibody and human complement: method for purging autologous bone marrow. Cancer Res 45:5969-5975, 1985 (Exhibit 62)

63. Munn DH, Cheung NK: Antibody-dependent antitumor cytotoxicity by human monocytes cultured with recombinant macrophage colony-stimulating factor. Induction of efficient antibody-mediated antitumor cytotoxicity not detected by isotope release assays. J Exp Med 170:511-526, 1989 (Exhibit 63)

64. Munn DH, Cheung NK: Phagocytosis of tumor cells by human monocytes cultured in recombinant macrophage colony-stimulating factor. J Exp Med 172:231-237, 1990 (Exhibit 64)

65. Sabzevari H, Gillies SD, Mueller BM, et al: A recombinant antibody-interleukin 2 fusion protein suppresses growth of hepatic human neuroblastoma metastases in severe combined immunodeficiency mice. Proceeds of the National Academy of Science USA 91:9626-9630, 1994 (Exhibit 65)

66. Mujoo K, Reisfeld RA, Cheung L, Rosenblum MG: A potent and specific immunotoxin for tumor cells expressing disialoganglioside GD2. Cancer Immunol Immunother 34:198-204, 1991 (Exhibit 66)

67. Gottstein C, Schön G, Tawadros S, et al: Antidisialoganglioside Ricin A-chain immunotoxins show potent anti-tumor effects in vitro and in a disseminated human neuroblastoma severe combined immunodeficiency mouse model. Cancer Res 54:6186-6193, 1994 (Exhibit 67)

68. Holzer U, Bethge W, Krull F, et al: Superantigen-staphylococcal-enterotoxin-A-dependent and antibody-targeted lysis of GD2-positive neruoblastoma cells. Cancer Immunol Immunother 41:129-136, 1995 (Exhibit 68)

69. Cheung NK, Lazarus H, Miraldi FD, et al: Ganglioside GD2 specific monoclonal antibody 3F8- a phase I study in patients with neuroblastoma and malignant melanoma. J Clin Oncol 5:1430-1440, 1987 (Exhibit 69)

70. Cheung NK, Lazarus H, Miraldi FD, et al: Reassessment of patient response to monoclonal antibody 3F8. J Clin Oncol 10:671-672, 1992(Exhibit 70)

71. Murray JL, Cunningham JE, Brewer H, et al: Phase I trial of murine monoclonal antibody 14G2a administered by prolonged intravenous infusion in patients with neuroectodermal tumors. J Clin Oncol 12:184-193, 1994 (Exhibit 71)

72. Uttenreuther-Fischer MM, Huang C-S, Reisfeld RA, Yu AL: Pharmacokinetics of anti-ganglioside GD2 mAb 14G2a in phase 1 trial in pediatric cancer patients. Cancer Immunol Immunother 41:29-36, 1995 (Exhibit 72)

73. Handgretinger R, Baader P, Dopfer R, et al: A phase I study of neuroblastoma with the anti-ganglioside GD2

antibody 14.G2a. Cancer Immunol Immunother 35:199-204, 1992 (Exhibit 73)

74. Miraldi FD, Nelson AD, Kraly C, et al: Diagnostic imaging of human neuroblastoma with radiolabeled antibody. Radiology 161:413-418, 1986 (Exhibit 74)

75. Arbit E, Yeh SJ, Cheung NK, Larson SM: Quantitative Immunoimaging of gliomas in humans with anti-ganglioside monoclonal antibodies. J Neurosurg 76:399a, 1991 (Exhibit 75)

76. Grant SC, Kostacoglu L, Kris MG, et al: Radioimmunodetection of small-cell lung cancer using the anti-GD2 ganglioside monoclonal antibody 3F8: a pilot trial. Eur J Nucl Med 23:145-149, 1996 (Exhibit 76)

77. Larson SM, Pentlow KS, Volkow ND, et al: PET scanning of iodine-124-3F8 as an approach to tumor dosimetry during treatment planning for radioimmunotherapy in a child with neuroblastoma. J Nucl Med 33:2020-2023, 1992 (Exhibit 77)

78. Pentlow KS, Graham MC, Lambrecht RM, et al: Quantitative imaging of I-124 using positron emission tomography with applications to radioimmunodiagnosis and radioimmunotherapy. Medical Physics 18:357-366, 1991 (Exhibit 78)

79. Pentlow KS, Graham MC, Lambrecht RM: Quantitative imaging of iodine-124 with PET. J Nucl Med 37:1557-1562, 1996 (Exhibit 79)

80. Saleh MN, Khazaeli MB, Wheeler RH, et al: A phase I trial of the murine monoclonal anti-GD2 antibody 14.G2a in metastatic melanoma. Cancer Res 52:4342-4347, 1992 (Exhibit 80)

81. Cheung NK, Cheung IY, Canete A, et al: Antibody response to murine anti-GD2 monoclonal antibodies: Correlation with patient survival. Cancer Res 54:2228-2233, 1994 (Exhibit 81)

82. Drengler RL, Kuhn JG, Schaaf LJ, et al: Phase I and pharmacokinetic trial of oral irinotecan administered daily for 5 days every 3 weeks in patients with solid tumors. J Clin Oncol 17:685-696, 1999 (Exhibit 82)

83. Cheung NK, Landmeier B, Neely J, et al: Complete tumor ablation with iodine 131-radiolabeled disialoganglioside GD2 specific monoclonal antibody against human neuroblastoma xenografted in nude mice. J Natl Cancer Inst 77:739-745, 1986 (Exhibit 83)

84. Cheung NK, Canete A, Cheung IY, et al: Disialoganglioside GD2 anti-idiotypic monoclonal antibodies. Int J Cancer 54:499-505, 1993 (Exhibit 84)

85. Loh A, Sgouros G, O'Donoghue JA, et al: A pharmacokinetic model of 131I-G250 antibody in patients with renal cell carcinoma. J Nucl Med 3:484-489, 1998 (Exhibit 85)

86. Kolbert KS, Sgouros G, Scott AM, et al: Implementation and evaluation of patient-specific three dimensional internal dosimetry. J Nucl Med 38:301-308, 1997 (Exhibit 86)

87. Sgouros G, Jureidini IM, Scott AM, et al: Bone marrow dosimetry: Regional variability of marrow-localizing antibody. J Nucl Med 37:695-698, 1996 (Exhibit 87)

88. Sgouros G, Deland D, Loh AC, et al: Marrow and whole-body absorbed dose vs marrow toxicity following 131I-G250 antibody therapy in patients with renal-cell carcinoma. J Nucl Med 38:252P, 1997 (Exhibit 88)

89. Furhang EE, Sgouros G, Chui CS: Radionuclide photon dose kernels for internal emitter dosimetry. Medical Physics 23:759-764, 1996 (Exhibit 89)

90. Furhang EE, Chui CS, Sgouros G: A monte carlo approach to patient-specific dosimetry. Medical Physics 23:1523-1529, 1996 (Exhibit 90)

91. Furhang EE, Chui CS, Kolbert KS, et al: Implementation of a monte carlo dosimetry method for

patient-specific internal emitter therapy. Medical Physics 24:1163-1172, 1997 (Exhibit 91)

92. Scott AM, Macapinlac H, Zhang J, et al: Image registration of SPECT and CT images using an external fiduciary band and three-dimensional surface fitting in metastatic thyroid cancer. J Nucl Med 36:100-103, 1995 (Exhibit 92)

93. Sgouros G, Chiu S, Pentlow KS, et al: Three-dimensional dosimetry for radioimmunotherapy treatment planning. J Nucl Med 34:1595-1601, 1993 (Exhibit 93)

94. Arndt CA, Crist WM. Common musculoskeletal tumors of childhood and adolescence. N Engl J Med. 1999;341:342-52 (Exhibit 94)

95. West DC, Grier HE, Swallow MM, Demetri GD, Granowetter L, Sklar J. Detection of circulating tumor cells in patients with Ewing's sarcoma and peripheral primitive neuroectodermal tumor. J Clin Oncol. 1997;15:583-8. (Exhibit 95)

96. de Alava E, Lozano MD, Patino A, Sierrasesumaga L, Pardo-Mindan FJ. Ewing family tumors: potential prognostic value of reverse- transcriptase polymerase chain reaction detection of minimal residual disease in peripheral blood samples. Diagn Mol Pathol. 1998;7:152-7. (Exhibit 96)

97. Toretsky JA, Neckers L, Wexler LH. Detection of (11;22)(q24;q12) translocation-bearing cells in peripheral blood progenitor cells of patients with Ewing's sarcoma family of tumors. J Natl Cancer Inst. 1995;87:385-6. (Exhibit 97)

98. Burdach S, Jurgens H, Peters C, et al. Myeloablative radiochemotherapy and hematopoietic stem-cell rescue in poor-prognosis Ewing's sarcoma. J Clin Oncol. 1993;11:1482-8. (Exhibit 98)

99. Chan KW, Petropoulos D, Choroszy M, et al. High-dose sequential chemotherapy and autologous stem cell reinfusion in advanced pediatric solid tumors. Bone Marrow Transplant. 1997;20:1039-43. (Exhibit 99)

100. Fischmeister G, Zoubek A, Jugovic D, et al. Low incidence of molecular evidence for tumour in PBPC harvests from patients with high risk Ewing tumours. Bone Marrow Transplant. 1999;24:405-9. (Exhibit 100)

101. Horowitz ME, Kinsella TJ, Wexler LH, et al. Total-body irradiation and autologous bone marrow transplant in the treatment of high-risk Ewing's sarcoma and rhabdomyosarcoma. J Clin Oncol. 1993;11:1911-8. (Exhibit 101)

102. Perentesis J, Katsanis E, DeFor T, Neglia J, Ramsay N. Autologous stem cell transplantation for high-risk pediatric solid tumors. Bone Marrow Transplant. 1999;24:609-15. (Exhibit 102)

103. Chirgwin JM, Przybyla AE, MacDonald RJ, Rutter WJ. Isolation of biologically active ribonucleic acid from sources enriched in ribonuclease. Biochemistry. 1979;18:5294-9. (Exhibit 103)

104. Mackall CL, Gress RE. Pathways of T-cell regeneration in mice and humans: implications for bone marrow transplantation and immunotherapy. Immunol Rev. 1997;157:61-72. (Exhibit 104)

105. Vogel W, Scheding S, Kanz L, Brugger W. Clinical applications of CD34(+) peripheral blood progenitor cells (PBPC). Stem Cells. 2000;18:87-92. (Exhibit 105)

106. Dyson PG, Horvath N, Joshua D, et al. CD34+ selection of autologous peripheral blood stem cells for transplantation following sequential cycles of high-dose therapy and mobilisation in multiple myeloma [In Process Citation]. Bone Marrow Transplant. 2000;25:1175-84. (Exhibit 106)

107. Emig M, Saussele S, Wittor H, et al. Accurate and rapid analysis of residual disease in patients with CML using specific fluorescent hybridization probes for real

time quantitative RT-PCR. Leukemia. 1999;13:1825-32. (Exhibit 107)

108. Mensink E, van de Locht A, Schattenberg A, et al. Quantitation of minimal residual disease in Philadelphia chromosome positive chronic myeloid leukaemia patients using real-time quantitative RT-PCR. Br J Haematol. 1998;102:768-74. (Exhibit 108)

109. Pongers-Willemse MJ, Verhagen OJ, Tibbe GJ, et al. Real-time quantitative PCR for the detection of minimal residual disease in acute lymphoblastic leukemia using junctional region specific TaqMan probes. Leukemia. 1998;12:2006-14. (Exhibit 109)

110. Branford S, Hughes TP, Rudzki Z. Monitoring chronic myeloid leukaemia therapy by real-time quantitative PCR in blood is a reliable alternative to bone marrow cytogenetics. Br J Haematol. 1999;107:587-99. (Exhibit 110)

111. Chang H.R., Cordon-Cardo C., Houghton A.N., Cheung N.K., and Brennan M.F., Expression of disialogangliosides GD2 and GD3 on human soft tissue sarcomas. Cancer 70: 633-8, (1992) (Exhibit 111)

112. Froberg, K., Brown, R.E.,, Gaylord, H.,, Manivel, C., Intra-abdominal desmoplastic small round cell tumor: immunohistochemical evidence for up-regulation of

autocrine and paracrine growth factors. Ann Clin Lab Sci 29: 78-85, 1999 (Exhibit 112)

113. Heiner, J.P., Miraldi, F., Kallick, S., Makley J., Neely, J., Smith-Mensah, W.H., and Cheung N.K. Localization of GD2- specific monoclonal antibody 3F8 in human osteosarcoma. Cancer Res. 47: 5377-81 (1987) (Exhibit 113)

114. Kushner, B.H., LaQuaglia M.P., Wollner, N., Meyers, P.A., Lindsley, K.L., Ghavimi, F., Merchant, T.E., Boulad, F., Cheung, N.K., Bonilla, M.A., Crouch, G., Kelleher, J.F., Steinherz, P.G., and Gerald, W.L., Desmoplastic small round-cell tumor: prolonged progression-free survival with aggressive multimodality therapy. J.Clin. Oncol. 14: 1526-31, (1996) (Exhibit 114)

115. Ladanyi, M., and Gerald, W., Fusion of the EWS and WT1 genes in the desmoplastic small round cell tumor. Cancer Res. 54: 2837-40, (1994) (Exhibit 115)

116. Gerald, W.L., Miller, H.K., Battifora,H., Miettenen, M., Silva, E.G., and Rosai, J.,Intrabdominal desmoplastic small round cell tumor. Report of 19 cases of a distinctive type of high-grade polyphenotypic malignancy affecting young individuals. Am. L. Surg. Pathol. 15, 499-513, (1991) (Exhibit 116)

117. Gerald, W.L., Ladanyi, M.L., De Alava, E., Cuatrecasas, M., Kushner, B.H., LaQuaglia, M.P., and Rosai, J. Clinical pathologic, and molecular spectrum of tumors associated with t(11;22)(p13;q12): desmoplastic small round-cell tumor and its variants. J. Clin. Oncol., 16: 3028-36, (1998) (Exhibit 117)

118. Ordonez, N.G., El-Naggar, A.K., Ro, J.Y., Silva, E.G., Mackay B., Intra-abdominal desmoplastic small cell tumor: a light microscopic, immunocytochemical, ultrastructural, and flow cytometric study. Hum. Pathol. 24, 850-65, (1993) (Exhibit 118)

119. Ordonez, N.G. Desmoplastic small round cell tumor: II: an ultrastructural and immunohistochemical study with emphasis on new immunohistochemical markers. Am. J. Surg. Pathol. 22: 1314-27, (1998) (Exhibit 119)

120. Adams, G.P., McGartney, J.E., Tai, M.-S., Oppermann, H., Huston, J.S., Stafford, W.F., Bookman, M.A., Fand, I., Houston, L.L. and Weiner, L.W. (1993) Highly specific in vivo tumor targeting by monovalent and divalent forms of 741F8 anti-c-erbB-2 single-chain Fv. Cancer Research 53, 4026-4034. (Exhibit 120)

121. Alt, M., Muller, R. and Kontermann, R.E. (1999) Novel tetravalent and bispecific IgG-like antibody molecules combining single-chain diabodies with the immunoglobulin

y1 Fc or CH3 region. FEBS Letters 454, 90-94. (Exhibit 121)

122. Bird, R.E., Hardman, K.D., Jacobson, J.W., Johnson, S., Kaufman, B.M., Lee, S.M., Lee, T., Pope, S.H., Riordan, G.S. and Whitlow, M. (1988) Single-chain antigen-binding proteins. Science 242, 423-426. (Exhibit 122)

123. Brocks, B., Rode, H.J., Klein, M., Gerlach, E., Dubel, S., Little, M., Pfizenmaier, K. and Moosmayer, D. (1997) A TNF receptor antagonistic scFv, which is not secreted in mammalian cells, is expressed as a soluble mono- and bivalent scFv derivative in insect cells. Immunotechnology 3, 173-84. (Exhibit 123)

124. Cai, X. and Garen, A. (1995) Anti-melanoma antibodies from melanoma patients immunized with genetically modified autologous tumor cells: selection of specific antibodies from single-chain Fv fusion phage libraries. Proceedings of the National Academy of Sciences of the United States of America 92, 6537-41. (Exhibit 124)

125. Ghetie, M.A., Podar, E.M., Ilgen, A., Gordon, B.E., Uhr, J.W. and Vitetta, E.S. (1997) Homodimerization of tumor-reactive monoclonal antibodies markedly increases their ability to induce growth arrest or apoptosis of tumor cells. Proceedings of the National Academy of

Sciences of the United States of America 94, 7509-14. (Exhibit 125)

126. Huston, J.S., Levinson, D., Mudgett-Hunter, M., Tai, M.S., Novotny, J., Margolies, M.N., Ridge, R.J., Bruccoleri, R.E., Haber, E. and Crea, R. (1988) Protein engineering of antibody binding sites: recovery of specific activity in an anti-digoxin single-chain Fv analogue produced in Escherichia coli. Proceedings of the National Academy of Sciences of the United States of America 85, 5879-83. (Exhibit 126)

127. Kato, T., Sato, K., Suzuki, S., Sasakawa, H., Kurokawa, M., Nishioka, K. and Yamamoto, K. (1995) Mammalian expression of single chain variable region fragments dimerized by Fc regions. Molecular Biology Reports 21, 141-146. (Exhibit 127)

128. Laemmli, U.K. (1970) Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227, 680-85. (Exhibit 128)

129. Lu, J. and Sloan, S.R. (1999) An alternating selection strategy for cloning phage display antibodies. Journal of Immunological Methods 228, 109-119. (Exhibit 129)

130. Michael, N.P., Chester, K.A., Melton, R.G., Robson, L., Nicholas, W., Boden, J.A., Pedley, R.B., Begent,

R.H., Sherwood, R.F. and Minton, N.P. (1996) In vitro and in vivo characterisation of a recombinant carboxypeptidase G2::anti-CEA scFv fusion protein. Immunotechnology 2, 47-57. (Exhibit 130)

131. Modak, S., Kramer, K., Humayun, G., Guo, H.F. and Cheung, N.K.V. (2001) Monoclonal antibody 8H9 targets a novel cell surface antigen expressed by a wide spectrum of human solid tumors. Cancer Research 61, 4048-4054. (Exhibit 131)

132. Powers, D.B., Amersdorfer, P., Poul, M.A., Nielsen, U.B., Shalaby, R., Adams, G.P., Weiner, L.M. and Marks, J.D. (2001) Expression of single-chain Fv-Fc fusions in pinchia pastoris. Journal of Immunological Methods 251, 123-135. (Exhibit 132)

133. Raag, R. and Whitlow, M. (1995) Single-chain Fvs. FASEB Journal 9, 73-80. (Exhibit 133)

134. Schultz, J., Lin, Y., Sanderson, J., Zuo, Y., Stone, D., Mallett, R., Wilbert, S. and Axworthy, D. (2000) A tetravalent single-chain antibody-streptavidin fusion protein for pretargeted lymphoma therapy. Cancer Research 60, 6663-6669. (Exhibit 134)

135. Shu, L., Qi, C.F., Schlom, J. and Kashmiri, S.V. (1993) Secretion of a single-gene-encoded immunoglobulin from myeloma cells. Proceedings of the National Academy

of Sciences of the United States of America 90, 7995-9. (Exhibit 135)

136. Thanavala, Y.M., Brown, S.E., Howard, C.R., Roitt, I.M. and Steward, M.W. (1986) A surrogate hepatitis B virus antigenic epitope represented by a synthetic peptide and an internal image antiidiotype antibody. Journal of Experimental Medicine 164, 227-236. (Exhibit 136)

137. Towbin, H., Staehelin, T. and Gordon, J. (1979) Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. Proceedings of the National Academy of Sciences of the United States of America 76, 4350-4. (Exhibit 137)

138. Tur, M.K., Huhn, M., Sasse, S., Engert, A. and Barth, S. (2001) Selection of scFv phages on intact cells under low pH conditions leads to a significant loss of insert-free phages. Biotechniques 30, 404-413. (Exhibit 138)

139. Umana, P., Jean-Mairet, J., Moudry, R., Amstutz, H. and Bailey, J.E. (1999) Engineered glycoforms of an antineuroblastoma IgG1 with optimized antibody-dependent cellular cytotoxic activity. Nature Biotechnology 17, 176-180. (Exhibit 139)

140. Wagner, U., Schlebusch, H., Kohler, S., Schmolling, J., Grunn, U. and Krebs, D. (1997) Immunological responses to the tumor-associated antigen CA125 in patients with advanced ovarian cancer induced by the murine monoclonal anti-idiotype vaccine ACA125. Hybridoma 16, 33-40. (Exhibit 140)

141. Wang, B., Chen, Y.B., Ayalon, O., Bender, J. and Garen, A. (1999) Human single-chain Fv immunoconjugates targeted to a melanoma-associated chondroitin sulfate proteoglycan mediate specific lysis of human melanoma cells by natural killer cells and complement. Proceedings of the National Academy of Sciences of the United States of America 96, 1627-32. (Exhibit 141)

142. Watters, J.M., Telleman, P. and Junghans, R.P. (1997) An optimized method for cell-based phage display panning. Immunotechnology 3, 21-9. (Exhibit 142)

143. Winter, G. and Milstein, C. (1991) Man-made antibodies. Nature 349, 293-299. (Exhibit 143)

144. Wright, A. and Morrison, S.L. (1997) Effect of glycosylation on antibody function: implications for genetic engineering. Trends in Biotechnology 15, 26-31. (Exhibit 144)

145. Wu, A.M., Chen, W., Raubitschek, A., Williams, L.E., Neumaier, M., Fischer, R., Hu, S.Z., Odom-Maryon, T.,

Wong, J.Y. and Shively, J.E. (1996) Tumor localization of anti-CEA single-chain Fvs: improved targeting by non-covalent dimers. Immunotechnology 2, 21-36. (Exhibit 145)

146. Stancovski, I., Schindler, D. G., Waks, T., Yarden, Y., Sela, M., and Eshhar, Z. Targeting of T lymphocytes to Neu/HERe-expressing cells using chimeric single chain Fv receptors. J Immunol, 151: 6577-6582, 1993. (Exhibit 146)

147. Moritz, D., Wels, W., Mattern, J., and Groner, B. Cytotoxic T lymphocytes with a grafted recognition specificity for ERBB2-expressing tumor cells. Proc. Natl Acad Sci, USA, 91: 4318-4322, 1994. (Exhibit 147)

148. Wels, W., Moritz, D., Schmidt, M., Jeschke, M., Hynes, N. E., and Groner, B. Biotechnological and gene therapeutic strategies in cancer treatment. Gene, 159: 73-80, 1995. (Exhibit 148)

149. Eshhar, Z., Waks, T., Bendavid, A., and Schindler, D. G. Functional expression of chimeric receptor genes in human T cells. J Immunol Methods, 248: 67-76, 2001. (Exhibit 149)

150. Wei, M. X., Tamiya, T., and Chase, M. Experimental tumor therapy in mice using the cyclophosphamide-

activating cytochrome P450 2B1 gene. Hum Gene Ther, 5: 969, 1994. (Exhibit 150)

151. Weijtens, M. E., Willemsen, R. A., Valerio, D., Stam, K., and Bolhuis, R. L. Single chain Ig/gamma gene-redirected human T lymphocytes produce cytokines, specifically lyse tumor cells, and recycle lytic capacity. J Immunol, 157: 836-843, 1996. (Exhibit 151)

152. Finney, H. M., Lawson, A. D. G., Bebbington, C. R., and Weir, N. C. Chimeric receptors providing both primary and costimulatory signaling in T cells from a single gene product. J Immunol, 161: 2791-2797, 1998. (Exhibit 152)

153. Koehne, G., Gallardo, H. F., Sadelain, M., and O'Reilly, R. J. Rapid selection of antigen-specific T lymphocytes by retroviral transduction. Blood, 96: 109-117, 2000. (Exhibit 153)

154. Bunnell, B. A., Muul, L. M., Donahue, R. E., Blaese, R. M., and Morgan, R. A. High-efficiency retroviral-mediated gene transfer into human nonhuman primate peripheral blood lymphocytes. Proceeds of the National Academy of Science,USA, 92: 7739-7743, 1995. (Exhibit 154)

155. Miller, A. D., Garcia, J. V., von Suhr, N., Lynch, C. M., Wilson, C., and Eiden, M. V. Construction and

properties of retrovirus packaging cells based on gibbon ape leukemia virus. J Virol, 1991: 2220-2224, 1991. (Exhibit 155)

156. Lam, J. S., Reeves, M. E., Cowherd, R., Rosenberg, S. A., and Hwu, P. Improved gene transfer into human lymphocytes using retroviruses with gibbon ape leukemia virus envelope. Hum Gene Ther, 7: 1415-1422, 1996. (Exhibit 156)

157. Bonini, C., Ferrari, G., Verzeletti, S., Servida, P., Zappone, E., Ruggieri, L., Ponzoni, M., Rossini, S., Mavilio, F., Traversari, C., and Bordignon, C. HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia. Science, 276: 1719-1723, 1997. (Exhibit 157)

158. Pollok, K. E., Hanenberg, H., Noblitt, T. W., Schroeder, W. L., Kato, I., Emanuel, D., and Williams, D. A. High-efficiency gene transfer into normal and adenosine deaminase-deficient T lymphocytes is mediated by transduction on recombinant fibronectin fragments. J Virol, 72: 4882-4892, 1998. (Exhibit 158)

159. Galea-Lauri, J., Darling, D., Gan, S.-U., Krivochtchapov, L., Kuiper, M., Gaken, J., Souberbielle, B., and Farzaneh, F. Expression of a variant of CD28 on a subpopulation of human NK cells: implications for B7-

mediated stimulation of NK cells. J Immunol, 163: 62-70, 1999. (Exhibit 159)

160. Patel, S. D., Moskalenko, M., Smith, D., Maske, B., Finer, M. H., and McArther, J. G. Impact of chimeric immune receptor extracellular protein domains on T cell function. Gene Therapy, 6: 412-419, 1999. (Exhibit 160)

161. Fitzer-Attas, C. J., Schindler, D. G., Waks, T., and Eshhar, Z. Harnessing Syk familytyrosine kinases as signaling domains for chimeric single chain of the variable domain receptors: optional design for T cell activation. J Immunol, 160: 145-154, 1998. (Exhibit 161)

162. Varez-Vallina, L. and Russell, S. J. Efficient discrimination between different densities of target antigen by tetracycline-regulatable T bodies. Hum Gene Ther, 10: 559-563, 1999. (Exhibit 162)

163. Yee, C., Riddell, S. R., and Greenberg, P. D. In vivo tracking of tumor-specific T cells. Curr Opin Immunol, 13: 141-146, 2001. (Exhibit 163)

164. Xiaoning, R. T., Ogg, G. S., Hansasuta, P., Dong, T., Rostron, T., Luzzi, G., Conlon, C. P., Screaton, G. R., McMichael, A. J., and Rowland-Jones, S. Rapid death of adoptively transferred T cells in acquired immunodeficiency syndrome. Blood, 93: 1506-1510, 1999. (Exhibit 164)

165. Riddell, S. R., Elliott, M., Lewinsohn, D. A., Gilbert, M. J., Wilson, L., Manley, S. A., Lupton, S. D., Overell, R. W., Reynolds, T. C., Corey, L., and Greenberg, P. D. T-cell mediated rejection of gene-modified HIV-specific cytotoxic T lymphocytes in HIV-infected patients. Nat Med, 2: 216-223, 1996. (Exhibit 165)

166. Crist W, Gehan EA, Ragab AH, Dickman PS, Donaldson SS, Fryer C, Hammond D, Hays DM, Herrmann J and Heyn R. The Third Intergroup Rhabdomyosarcoma Study J Clin Oncol 13:610-30, 1995 (Exhibit 166)

167. Maurer HM, Gehan EA, Beltangady M, Crist W, Dickman PS, Donaldson SS, Fryer C, Hammond D, Hays DM and Herrmann J. The Intergroup Rhabdomyosarcoma Study-II. Cancer 71:1904-22, 1993 (Exhibit 167)

168. Weigel BJ, Breitfeld PP, Hawkins D, Crist WM, and Baker KS.. Role of high-dose chemotherapy with hematopoietic stem cell rescue in the treatment of metastatic or recurrent rhabdomyosarcoma. J Pediatr Hematol Oncol 23:272-276, 2001 (Exhibit 168)

169. Kramer K, Cheung NK, Humm JL, Dantis E, Finn R, Yeh SJ, Antunes NL, Dunkel IJ, Souwedaine M and Larson SM. Targeted radioimmunotherapy for leptomeningeal cancer

using (131)I-3F8. Med Pediatr Oncol 35:716-8, 2000 (Exhibit 169)

170. Kumar S, Perlaman, E, Harris CA, Raffeld M and Tsokos M. Myogenin is a specific marker for rhabdomyosarcoma: an immunohistochemical study in paraffin embedded tissues. Mod Pathol 13: 988-93, 2000 (Exhibit170)

171. Gattenloehner S, Vincent A, Leuschner I, Tzartos S, Muller-Hermelink HK, Kirchner T and Marx A. The fetal form of the acetylcholine receptor distinguishes rhabdomyosarcomas from other childhood tumors. Am J Pathol. 152:437-44, 1998 (Exhibit 171)

172. Truong LD, Rangdaeng S, Cagle P, Ro JY, Hawkins H, Font RL. The diagnostic utility of desmin. A study of 584 cases and review of the literature Am J Clin Pathol 93:305-14, 1990 (Exhibit 172)

173. Qualman SJ, Coffin CM, Newton WA, Hojo H, Triche TJ, Parham DM, and Crist WM. Intergroup Rhabdomyosarcoma Study: update for pathologists Pediatr Dev Pathol 1:550-61, 1998 (Exhibit 173)

174. Strother DR, Parham DM and Houghton PJ. Expression of the 5.1 H11 antigen, a fetal muscle surface antigen, in normal and neoplastic tissue. Arch Pathol Lab Med 114:593-596, 1990 (Exhibit 174)

175. Merino ME, Navid F, Christensen BL, Toretsky JA, Helman LJ, Cheung NK and Mackall CL. Immunomagnetic purging of ewing's sarcoma from blood and bone marrow: quantitation by real-time polymerase chain reaction. J Clin Oncol 19:3649-3659, 2001 (Exhibit 175)

If a telephone interview would be of assistance in advancing prosecution of the subject application, Applicant's undersigned attorney invites the Examiner to telephone him at the number provided below.

No fee is deemed necessary in connection with the filing of this Information Disclosure Statement (§1.97(c)). However, if any additional fee is required, authorization is hereby given to charge the amount of any such fee to Applicant's Deposit Account No. 50-1891.

Respectfully submitted,

Albert Wai-Kit Chan

Albert Wai-Kit Chan
Registration No. 36,479
Attorney for Applicant
141-07 20th Ave., Suite 604
Whitestone, NY 11357
Tel: (718) 357-8836
Fax: (718) 357-8552

I hereby certify that this paper is being deposited this date with the U.S. Postal Service as first class mail addressed to: U.S. Patent and Trademark Office, Attn: Assistant Commissioner for Patents, Washington, D.C. 20231.

Albert Wai-Kit Chan 1/23/02

Albert Wai-Kit Chan Date
Reg. No. 36,479

Form PTO-1449 U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. 638-A	Serial No. 09/982,645
INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)	Applicants CHEUNG, Nai-Kong V.	
	Filing Date 10/18/01	Group 1645

U.S. PATENT DOCUMENTS

Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date if Appropriate

FOREIGN PATENT DOCUMENTS

		Document Number	Date	Country	Class	Subclass	Translation	
							Yes	No

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	1	Cheung, N. K. V. et al. Anti-GD2 antibody treatment of minimal residual stage 4 neuroblastoma diagnosed at more than 1 year of age. J. Clin. Oncol., *16*:3053-3060, 1998. **(Exhibit 1)**
	2	Yu, A. et al. et al. Phase I trial of a human-mouse chimeric anti-disialoganglioside monoclonal antibody ch14.18 in patients with refractory neuroblastoma and osteosarcoma. J. Clin. Oncol., *16*:2169-2180, 1998. **(Exhibit 2)**
	3	Jurcic, J. G. et al. Sequential targeted therapy for acute promyelocytic leukemia with all-trans retinoic acid and anti-CD33 monoclonal antibody M195. Leuk., *9*:244-248, 1995. **(Exhibit 3)**
	4	Czuczman, M. S. et al. Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy. J. Clin. Oncol., *17*:268-276, 1999. **(Exhibit 4)**

	5	Garin-Chesa, P. et al Immunohistochemical analysis of neural cell adhesion molecules. Differential expressionin small round cell tumors of childhood and adolescence. Am. J. Pathol., *139*:275-286, 1991. **(Exhibit 5)**
	6	Ritter, G. et al Ganglioside antigens expressed by human cancer cells. Semin. Cancer. Biol., *2*:401-409, 1991. **(Exhibit 6)**
	7	Ylagan et al. CD44 expression in astrocytic tumors. Modern Pathology, *10*:1239-1246, 1997. **(Exhibit 7)**
	8	Kuan, C. T. et al. 125I-labeled anti-epidermal growth factor receptor vIII single-chain Fv exhibits specific and high-level targeting of glioma xenografts. Clin. Can. Res., *5*:1539-1549, 1999. **(Exhibit 8)**
	9	Richardson, R. B. et al. Radioimmunolocalization of human brain tumors. Biodistribution of radiolabelled monoclonal antibody UJ13A. Eur J Nucl Med, *12*:313-320, 1986. **(Exhibit 9)**
	10	Papanastassiou, V. et al. Treatment of recurrent and cystic malignant gliomas by a single intracavitary injection of 131I-monoclonal antibody: Feasibility, pharmacokinetics and dosimetry. Br. J. Cancer, *67*:144-151, 1993. **(Exhibit 10)**
	11	Celis, E. et al. Induction of anti-tumor cytotoxic T lymphocytes in normal humans using primary cultures and synthetic peptide epitopes. Proc. Natl. Acad. Sci. USA, *91*:2105-2109, 1994. **(Exhibit 11)**
	12	Riva, P. et al. 131I radioconjugated antibodies for the locoregional radioimmunotherapy of high-grade malignant glioma- phase I and II study. Acta Oncol, *38*:351-359, 1999. **(Exhibit 12)**
	13	Heiner, J. et al. Localization of GD2 specific monoclonal antibody in human osteogenic sarcoma. Cancer Res., *47*:5377-5381, 1987. **(Exhibit 13)**
	14	Spendlove, I. et al. Decay accelerating factor (CD55): a target for cancer vaccines? Cancer Res., *59*:2282-2286, 1999. **(Exhibit 14)**
	15	Weidner, N. et al. Immunohistochemical profile of monoclonal antibody O13 that recognizes glycoprotein 930/32MIC2 and is useful in diagnosing ewing's sarcoma and peripheral neuroepithelioma. American Journal of Surgical Pathology, *18*:486-494, 1994. **(Exhibit 15)**
	16	Hatzubai, A. et al. The use of a monoclonal anti-idiotype antibody to study the biology of human B-cell lymphoma. J. Immunol., *126*:2397-2402, 1981. **(Exhibit 16)**

	17	Cheung, N. K. et al. Monoclonal antibodies to a glycolipid antigen on human neuroblastoma cells. Cancer Res., *45*:2642-2649, 1985. **(Exhibit 17)**
	18	Kramer, K. et al. Prognostic value of TrkA protein detection my monoclonal antibody 5C3 in Neuroblastoma. Clin. Can. Res., *2*:1361-1367, 1996. **(Exhibit 18)**
	19	Hecht, T. T. et al. Production and characterization of a monoclonal antibody that binds reed-sternberg cells. J. Immunol., *134*:4231-4236, 1985. **(Exhibit 19)**
	20	Seeger, R. C. et al. Danon, Y. L., Rayner, S. A., Hoover, F. Definition of a Thy-1 determinant on human neuroblastoma, glioma, sarcoma, and teratoma cells with a monoclonal antibody. J. Immunol., *128*:983-989, 1982. **(Exhibit 20)**
	21	Kaaijk, P. et al. Expression of CD44 splice variants in human primary brain tumors. Journal of Neuro- Oncology, *26*:185-190, 1995. **(Exhibit 21)**
	22	Wikstrand, C. J. et al. Lactotetraose series ganglioside 3',6'-isoLD1 in tumors of central nervous and other systems in vitro and in vivo. Cancer Res., *53*:120-126, 1993. **(Exhibit 22)**
	23	Pappo, A. et al. biology and treatment. Pediatr. Clin. North Am., *44*:953-972, 1997. **(Exhibit 23)**
	24	Fujisawa, T. et al. A monoclonal antibody with selective immunoreactivity for neuroblastoma and rhabdomyosarcoma. Proc. Am. Assoc. Cancer Res., *30*:345, 1989. **(Exhibit 24)**
	25	Wikstrand, C. J. et al. Monoclonal Antibodies against EGFRvIII are Tumor Specific and React with Breast and Lung Carcinomas and Malignant Gliomas. Cancer Res., *55*:3140-48, 1995. **(Exhibit 25)**
	26	Kishima, H. et al. Monoclonal antibody ONS-21 recognizes integrin a3 in gliomas and gliomas and medulloblastomas. Br. J. Cancer, *79*:333-339, 1998. **(Exhibit 26)**
	27	Moriuchi, S. et al. Characterization of a new mouse monoclonal antibody (ONS-M21) reactive with both medulloblastomas and gliomas. Br. J. Cancer, *68*:831-837, 1993. **(Exhibit 27)**
	28	Kondo, S. et al. Human glioma-specific antigens detected by monoclonal antibodies. Neurosurgery, *30*:506-511, 1992. **(Exhibit 28)**

	29	Dastidar, S. G. et al. Monoclonal antibody against human glioblastoma multiforme (U-87Mg) immunoprecipitates a protein of monoclonal mass 38Kda and inhibits tumor growth in nude mice. J Neuroimmuno, *56*:91-98, 1995. **(Exhibit 29)**
	30	Mihara, Y. et al. Monoclonal antibody against ependymoma-derived cell line. Journal of Neuro- Oncology, *12*:1-11, 1992. **(Exhibit 30)**
	31	Daghighian, F. et al. Development of a method to measure kinetics of radiolabeled monoclonal antibody in human tumour with applications to microdosimetry: positron emission tomography studies of iodine-124 labeled 3F8 monoclonal antibody in glioma. Eur J Nucl Med, *20*:402-409, 1993. **(Exhibit 31)**
	32	Plate, K. H. et al. Platelet derived growth factor b is induced during tumor development and upregulated during tumor progressing in endothelial cells in human gliomas. Lab. Invest., *67*:529-534, 1992. **(Exhibit 32)**
	33	Yang, H. S. et al. Expression of 300-kilodalton intermediate filament-associated protein distinguishes human glioma cells from normal astrocytes. Proceedings of the National Academy of Sciences of the United States of America, *90*:8534-8537, 1993. **(Exhibit 33)**
	34	Koehler G et al. Continuous culture of fused cells secreting antibody of pre-defined specificity. Nature 256:495-496, 1975 **(Exhibit 34)**
	35	Moffat R et al. Clinical utility of external immunoscintigraphy with the IMMU-4 technetium-99m Fab' antibody fragment in patients undergoing surgery for carcinoma of the colon and rectum:results of a pivotal, phase III trial. The Immunomedics Study Group. J Clin Oncol 14(8):2295-2305, 1996 **(Exhibit 35)**
	36	Maloney DG et al. IDEC-C2B8: Results of a phase I multiple-dose trial in patients with relapsed non-hodgkin's lymphoma. J Clin Oncol 15:3266-3274, 1997 **(Exhibit 36)**
	37	Cobleigh MA et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 17:2639-2648, 1999 **(Exhibit 37)**
	38	Meredith RF et al. Phase II study of dual 131I-labeled monoclonal antibody therapy with interferon in patients with metastatic colorectal cancer. Clin Can Res 2:1811-1818, 1996 **(Exhibit 38)**

	39	Yeh SD et al.
		Radioimmunodetection of neuroblastoma with iodine-131-3F8: Correlation with biopsy, iodine-131-Metaiodobenzylguanidine (MIBG) and standard diagnostic modalities. J Nucl Med 32:769-776, 1991 **(Exhibit 39)**
	40	Wheldon TE et al.
		The curability of tumors of differing size by targeted radiotherapy using 131-I or 90-Y. Radiother Oncol 21:91-99, 1991 **(Exhibit 40)**
	41	Wilder RB et al.
		Radioimmunotherapy: recent results and future directions. J Clin Oncol 14:1383-1400, 1996 **(Exhibit 41)**
	42	Zalutsky MR et al.
		Radioimmunotherapy of neoplastic meningitis in rats using an alpha-particle-emitting immunoconjugate. Cancer Res 54:4719-4725, 1994 **(Exhibit 42)**
	43	McDevitt MR et al.
		Radioimmunotherapy with alpha-emitting nuclides. Eur J Nucl Med 25:1341-1351, 1998 **(Exhibit 43)**
	44	DeNardo SJ et al.
		Antibody phage libraries for the next generation of tumor targeting radioimmunotherapeutics. Clin Can Res 5:3213s-3218s, 1999 **(Exhibit 44)**
	45	DeNardo SJ et al.
		Phage Library-derived human anti-TETA anti anti-DOTA ScFv for pretargeting RIT. Hybridoma 18:13-21, 1999 **(Exhibit 45)**
	46	Eshhar Z et al.
		Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the or zeta subunits of the immunoglobulin and T-cell receptors. Proc Natl Acad Sci USA 90:720-24, 1993 **(Exhibit 46)**
	47	Altenschmidt U et al.
		Cytolysis of tumor cells expressing the Neu/erbB-2, erbB-3, and erbB-4 receptors by genetically targeted I T lymphocytes. Clin Can Res 2:1001-1008, 1996 **(Exhibit 47)**
	48	Krause A et al.
		Antigen-dependent CD-28 signaling enhances survival and proliferation in genetically modified activated human primary T lymphocytes. J Exp Med 188:619-626, 1998 **(Exhibit 48)**
	49	Price MR et al.
		Characteristics of the cell surface antigen p72, associated with a variety of human tumors and mitogen-stimulated T-lymnphoblasts. FEBS Letters 171:31-35, 1984 **(Exhibit 49)**
	50	Gorlick R et al.
		Expression of HER2/erbB-2 correlates with survival in osteosarcoma. J Clin Oncol 17:2781-2788, 1999 **(Exhibit 50)**

	51	Cheung NK et al. Detection of metastatic neuroblastoma in bone marrow: when is routine marrow histology insensitive? J Clin Oncol 15:2807-2817, 1997 **(Exhibit 51)**
	52	Ghossein RA et al. Detection of circulating prostatic tumor cells using immunobead reverse transcriptase polymerase chain reaction for prostatic specific membrane antigen mRNA. Diag Mol Path 8:59-65, 1999 **(Exhibit 52)**
	53	Leung W et al. Frequent detection of tumor cells in hematopoietic grafts in neuroblastoma and ewing's sarcoma. Bone Marrow Transpl 22:971-979, 1998 **(Exhibit 53)**
	54	Mueller BM et al. Enhancement of antibody-dependent cytotoxicity with a chimeric anti-GD2 antibody. J Immunol 144:1382-1386, 1990 **(Exhibit 54)**
	55	Santos AD et al. Generation and characterization of a single gene-encoded single-chain-tetravalent antitumor antibody. Clin Can Res 5:3118s-3123s, 1999 **(Exhibit 55)**
	56	Guo HF et al. Recombinant anti-ganglioside GD2 scFv-streptavidin fusion protein for tumor pretargeting. Proc Am Assoc Cancer Res 37:469, 1996 (abstract) **(Exhibit 56)**
	57	Fagnou C et al. Presence of tumor cells in bone marrow but not in blood is associated with adverse prognosis in patients with ewing's tumor. J Clin Oncol 16:1707-1711, 1998 **(Exhibit 57)**
	58	Munn DH et al. Interleukin-2 enhancement of monoclonal antibody-mediated cellular cytotoxicity (ADCC) against human melanoma. Cancer Res 47:6600-6605, 1987 **(Exhibit 58)**
	59	Hank JA et al. Augmentation of antibody dependent cell mediated cytotoxicity following in vivo therapy with recombinant interleukin-2. Cancer Res 50:5234-5239, 1990 **(Exhibit 59)**
	60	Kushner BH et al. GM-CSF enhances 3F8 monoclonal antibody-dependent cellular cytotoxicity against human melanoma and neuroblastoma. Blood 73:1936-1941, 1989 **(Exhibit 60)**
	61	Kushner BH et al. Absolute requirement of CD11/CD18 adhesion molecules, FcRII and phosphatidylinositol-linked FcRIII for monoclonal antibody-mediated neutrophil anti-human tumor cytotoxicity. Blood 79:1484-1490, 19 **(Exhibit 61)**
	62	Saarinen UM et al. Eradication of neuroblastoma cells in vitro by monoclonal antibody and human complement: method for purging autologous bone marrow. Cancer Res 45:5969-5975, 1985 **(Exhibit 62)**

	63	Munn DH et al. Antibody-dependent antitumor cytotoxicity by human monocytes cultured with recombinant macrophage colony-stimulating factor. Induction of efficient antibody-mediated antitumor cytotoxicity not detected by isotope release assays. J Exp Med 170:511-526, 1989 **(Exhibit 63)**
	64	Munn DH et al. Phagocytosis of tumor cells by human monocytes cultured in recombinant macrophage colony-stimulating factor. J Exp Med 172:231-237, 1990 **(Exhibit 64)**
	65	Sabzevari H et al. A recombinant antibody-interleukin 2 fusion protein suppresses growth of hepatic human neuroblastoma metastases in severe combined immunodeficiency mice. Proceeds of the National Academy of Science USA 91:9626-9630, 1994 **(Exhibit 65)**
	66	Mujoo K et al. A potent and specific immunotoxin for tumor cells expressing disialoganglioside GD2. Cancer Immunol Immunother 34:198-204, 1991 **(Exhibit 66)**
	67	Gottstein C et al. Antidisialoganglioside Ricin A-chain immunotoxins show potent anti-tumor effects in vitro and in a disseminated human neuroblastoma severe combined immunodeficiency mouse model. Cancer Res 54:6186-6193, 1994 **(Exhibit 67)**
	68	Holzer U et al. Superantigen-staphylococcal-enterotoxin-A-dependent and antibody-targeted lysis of GD2-positive neruoblastoma cells. Cancer Immunol Immunother 41:129-136, 1995 **(Exhibit 68)**
	69	Cheung NK et al. Ganglioside GD2 specific monoclonal antibody 3F8- a phase I study in patients with neuroblastoma and malignant melanoma. J Clin Oncol 5:1430-1440, 1987 **(Exhibit 69)**
	70	Cheung NK et al. Reassessment of patient response to monoclonal antibody 3F8. J Clin Oncol 10:671-672, 1992 **(Exhibit 70)**
	71	Murray JL et al. Phase I trial of murine monoclonal antibody 14G2a administered by prolonged intravenous infusion in patients with neuroectodermal tumors. J Clin Oncol 12:184-193, 1994 **(Exhibit 71)**
	72	Uttenreuther-Fischer MM et al. Pharmacokinetics of anti-ganglioside GD2 mAb 14G2a in phase 1 trial in pediatric cancer patients. Cancer Immunol Immunother 41:29-36, 1995 **(Exhibit 72)**
	73	Handgretinger R et al. A phase I study of neuroblastoma with the anti-ganglioside GD2 antibody 14.G2a. Cancer Immunol Immunother 35:199-204, 1992 **(Exhibit 73)**

	74	Miraldi FD et al. Diagnostic imaging of human neuroblastoma with radiolabeled antibody. Radiology 161:413-418, 1986 **(Exhibit 74)**
	75	Arbit E et al. Quantitative Immunoimaging of gliomas in humans with anti-ganglioside monoclonal antibodies. J Neurosurg 76:399a, 1991 **(Exhibit 75)**
	76	Grant SC et al. Radioimmunodetection of small-cell lung cancer using the anti-GD2 ganglioside monoclonal antibody 3F8: a pilot trial. Eur J Nucl Med 23:145-149, 1996 **(Exhibit 76)**
	77	Larson SM et al. PET scanning of iodine-124-3F8 as an approach to tumor dosimetry during treatment planning for radioimmunotherapy in a child with neuroblastoma. J Nucl Med 33:2020-2023, 1992 **(Exhibit 77)**
	78	Pentlow KS et al. Quantitative imaging of I-124 using positron emission tomography with applications to radioimmunodiagnosis and radioimmunotherapy. Medical Physics 18:357-366, 1991 **(Exhibit 78)**
	79	Pentlow KS et al. Quantitative imaging of iodine-124 with PET. J Nucl Med 37:1557-1562, 1996 **(Exhibit 79)**
	80	Saleh MN et al. A phase I trial of the murine monoclonal anti-GD2 antibody 14.G2a in metastatic melanoma. Cancer Res 52:4342-4347, 1992 **(Exhibit 80)**
	81	Cheung NK et al. Antibody response to murine anti-GD2 monoclonal antibodies: Correlation with patient survival. Cancer Res 54:2228-2233, 1994 **(Exhibit 81)**
	82	Drengler RL et al. Phase I and pharmacokinetic trial of oral irinotecan administered daily for 5 days every 3 weeks in patients with solid tumors. J Clin Oncol 17:685-696, 1999 **(Exhibit 82)**
	83	Cheung NK et al. Complete tumor ablation with iodine 131-radiolabeled disialoganglioside GD2 specific monoclonal antibody against human neuroblastoma xenografted in nude mice. J Natl Cancer Inst 77:739-745, 1986 **(Exhibit 83)**
	84	Cheung NK et al. Disialoganglioside GD2 anti-idiotypic monoclonal antibodies. Int J Cancer 54:499-505, 1993 **(Exhibit 84)**
	85	Loh A et al. A pharmacokinetic model of 131I-G250 antibody in patients with renal cell carcinoma. J Nucl Med 3:484-489, 1998 **(Exhibit 85)**

	86	Kolbert KS et al. Implementation and evaluation of patient-specific three dimensional internal dosimetry. J Nucl Med 38:301-308, 1997 **(Exhibit 86)**
	87	Sgouros G et al. Bone marrow dosimetry: Regional variability of marrow-localizing antibody. J Nucl Med 37:695-698, 1996 **(Exhibit 87)**
	88	Sgouros G et al. Marrow and whole-body absorbed dose vs marrow toxicity following 131I-G250 antibody therapy in patients with renal-cell carcinoma. J Nucl Med 38:252P, 1997 **(Exhibit 88)**
	89	Furhang EE et al. Radionuclide photon dose kernels for internal emitter dosimetry. Medical Physics 23:759-764, 1996 **(Exhibit 89)**
	90	Furhang EE et al. A monte carlo approach to patient-specific dosimetry. Medical Physics 23:1523-1529, 1996 **(Exhibit 90)**
	91	Furhang EE et al. Implementation of a monte carlo dosimetry method for patient-specific internal emitter therapy. Medical Physics 24:1163-1172, 1997 **(Exhibit 91)**
	92	Scott AM et al. Image registration of SPECT and CT images using an external fiduciary band and three-dimensional surface fitting in metastatic thyroid cancer. J Nucl Med 36:100-103, 1995 **(Exhibit 92)**
	93	Sgouros G et al. Three-dimensional dosimetry for radioimmunotherapy treatment planning. J Nucl Med 34:1595-1601, 1993 **(Exhibit 93)**
	94	Arndt CA et al. Common musculoskeletal tumors of childhood and adolescence. N Engl J Med. 1999;341:342-52 **(Exhibit 94)**
	95	West DC et al. Detection of circulating tumor cells in patients with Ewing's sarcoma and peripheral primitive neuroectodermal tumor. J Clin Oncol. 1997;15:583-8. **(Exhibit 95)**
	96	de Alava E et al. Ewing family tumors: potential prognostic value of reverse-transcriptase polymerase chain reaction detection of minimal residual disease in peripheral blood samples. Diagn Mol Pathol. 1998;7:152-7. **(Exhibit 96)**
	97	Toretsky JA et al. Detection of (11;22)(q24;q12) translocation-bearing cells in peripheral blood progenitor cells of patients with Ewing's sarcoma family of tumors. J Natl Cancer Inst. 1995;87:385-6. **(Exhibit 97)**

	98	Burdach S et al.
		Myeloablative radiochemotherapy and hematopoietic stem-cell rescue in poor-prognosis Ewing's sarcoma. J Clin Oncol. 1993;11:1482-8. **(Exhibit 98)**
	99	Chan KW et al.
		High-dose sequential chemotherapy and autologous stem cell reinfusion in advanced pediatric solid tumors. Bone Marrow Transplant. 1997;20:1039-43. **(Exhibit 99)**
	100	Fischmeister G et al.
		Low incidence of molecular evidence for tumour in PBPC harvests from patients with high risk Ewing tumours. Bone Marrow Transplant. 1999;24:405-9. **(Exhibit 100)**
	101	Horowitz ME et al.
		Total-body irradiation and autologous bone marrow transplant in the treatment of high-risk Ewing's sarcoma and rhabdomyosarcoma. J Clin Oncol. 1993;11:1911-8. **(Exhibit 101)**
	102	Perentesis J et al.
		Autologous stem cell transplantation for high-risk pediatric solid tumors. Bone Marrow Transplant. 1999;24:609-15. **(Exhibit 102)**
	103	Chirgwin JM et al.
		Isolation of biologically active ribonucleic acid from sources enriched in ribonuclease. Biochemistry. 1979;18:5294-9. **(Exhibit 103)**
	104	Mackall CL et al.
		Pathways of T-cell regeneration in mice and humans: implications for bone marrow transplantation and immunotherapy. Immunol Rev. 1997;157:61-72. **(Exhibit 104)**
	105	Vogel W et al.
		Clinical applications of CD34(+) peripheral blood progenitor cells (PBPC). Stem Cells. 2000;18:87-92. **(Exhibit 105)**
	106	Dyson PG et al.
		CD34+ selection of autologous peripheral blood stem cells for transplantation following sequential cycles of high-dose therapy and mobilization in multiple myeloma [In Process Citation]. Bone Marrow Transplant. 2000;25:1175-84. **(Exhibit 106)**
	107	Emig M et al.
		Accurate and rapid analysis of residual disease in patients with CML using specific fluorescent hybridization probes for real time quantitative RT-PCR. Leukemia. 1999;13:1825-32. **(Exhibit 107)**
	108	Mensink E et al.
		Quantitation of minimal residual disease in Philadelphia chromosome positive chronic myeloid leukaemia patients using real-time quantitative RT-PCR. Br J Haematol. 1998;102:768-74. **(Exhibit 108)**

	109	Pongers-Willemse MJ et al.
		Real-time quantitative PCR for the detection of minimal residual disease in acute lymphoblastic leukemia using junctional region specific TaqMan probes. Leukemia. 1998;12:2006-14. **(Exhibit 109)**
	110	Branford S et al.
		Monitoring chronic myeloid leukaemia therapy by real-time quantitative PCR in blood is a reliable alternative to bone marrow cytogenetics. Br J Haematol. 1999;107:587-99. **(Exhibit 110)**
	111	Chang H.R. et al.
		Expression of disialogangliosides G_{D2} and G_{D3} on human soft tissue sarcomas. Cancer **70**: 633-8, (1992) **(Exhibit 111)**
	112	Froberg, K. et al.
		Intra-abdominal desmoplastic small round cell tumor: immunohistochemical evidence for up-regulation of autocrine and paracrine growth factors. Ann Clin Lab Sci **29:** 78-85, 1999 **(Exhibit 112)**
	113	Heiner, J.P. et al.
		Localization of G_{D2}- specific monoclonal antibody 3F8 in human osteosarcoma. Cancer Res. 47: 5377-81 (1987) **(Exhibit 113)**
	114	Kushner, B.H. et al.
		Desmoplastic small round-cell tumor: prolonged progression-free survival with aggressive multimodality therapy. J.Clin. Oncol. **14**: 1526-31, (1996) **(Exhibit 114)**
	115	Ladanyi, M. et al.
		Fusion of the EWS and WT1 genes in the desmoplastic small round cell tumor. Cancer Res. **54**: 2837-40, (1994) **(Exhibit 115)**
	116	Gerald, W.L. et al.
		Intrabdominal desmoplastic small round cell tumor. Report of 19 cases of a distinctive type of high-grade polyphenotypic malignancy affecting young individuals. Am. L. Surg. Pathol. **15**, 499-513, (1991) **(Exhibit 116)**
	117	Gerald, W.L. et al.
		Clinical pathologic, and molecular spectrum of tumors associated with t(11;22)(p13;q12): desmoplastic small round-cell tumor and its variants. J. Clin. Oncol., **16**: 3028-36, (1998) **(Exhibit 117)**
	118	Ordonez, N.G. et al.
		Intra-abdominal desmoplastic small cell tumor: a light microscopic, immunocytochemical, ultrastructural, and flow cytometric study. Hum. Pathol. **24,** 850-65, (1993) **(Exhibit 118)**
	119	Ordonez, N.G. et al.
		Desmoplastic small round cell tumor: II: an ultrastructural and immunohistochemical study with emphasis on new immunohistochemical markers. Am. J. Surg. Pathol. **22**: 1314-27, (1998) **(Exhibit 119)**

	120	Adams, G.P. et al.
		Highly specific in vivo tumor targeting by monovalent and divalent forms of 741F8 anti-c-erbB-2 single-chain Fv. Cancer Research 53, 4026-4034. **(Exhibit 120)**
	121	Alt, M. et al.
		Novel tetravalent and bispecific IgG-like antibody molecules combining single-chain diabodies with the immunoglobulin γ1 Fc or CH3 region. FEBS Letters 454, 90-94. **(Exhibit 121)**
	122	Bird, R.E. et al.
		Single-chain antigen-binding proteins. Science 242, 423-426. **(Exhibit 122)**
	123	Brocks, B. et al.
		A TNF receptor antagonistic scFv, which is not secreted in mammalian cells, is expressed as a soluble mono- and bivalent scFv derivative in insect cells. Immunotechnology 3, 173-84. **(Exhibit 123)**
	124	Cai, X. et al.
		Anti-melanoma antibodies from melanoma patients immunized with genetically modified autologous tumor cells: selection of specific antibodies from single-chain Fv fusion phage libraries. Proceedings of the National Academy of Sciences of the United States of America 92, 6537-41. **(Exhibit 124)**
	125	Ghetie, M.A. et al.
		Homodimerization of tumor-reactive monoclonal antibodies markedly increases their ability to induce growth arrest or apoptosis of tumor cells. Proceedings of the National Academy of Sciences of the United States of America 94, 7509-14. **(Exhibit 125)**
	126	Huston, J.S. et al.
		Protein engineering of antibody binding sites: recovery of specific activity in an anti-digoxin single-chain Fv analogue produced in Escherichia coli. Proceedings of the National Academy of Sciences of the United States of America 85, 5879-83. **(Exhibit 126)**
	127	Kato, T. et al.
		Mammalian expression of single chain variable region fragments dimerized by Fc regions. Molecular Biology Reports 21, 141-146. **(Exhibit 127)**
	128	Laemmli, U.K. et al.
		Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227, 680-85. **(Exhibit 128)**
	129	Lu, J. et al.
		An alternating selection strategy for cloning phage display antibodies. Journal of Immunological Methods 228, 109-119. **(Exhibit 129)**
	130	Michael, N.P. et al.
		In vitro and in vivo characterisation of a recombinant carboxypeptidase G2::anti-CEA scFv fusion protein. Immunotechnology 2, 47-57. **(Exhibit 130)**

	131	Modak, S. et al.
		Monoclonal antibody 8H9 targets a novel cell surface antigen expressed by a wide spectrum of human solid tumors. Cancer Research 61, 4048-4054. **(Exhibit 131)**
	132	Powers, D.B. et al.
		Expression of single-chain Fv-Fc fusions in pinchia pastoris. Journal of Immunological Methods 251, 123-135. **(Exhibit 132)**
	133	Raag, R. et al.
		Single-chain Fvs. FASEB Journal 9, 73-80. **(Exhibit 133)**
	134	Schultz, J. et al.
		A tetravalent single-chain antibody-streptavidin fusion protein for pretargeted lymphoma therapy. Cancer Research 60, 6663-6669. **(Exhibit 134)**
	135	Shu, L. et al.
		Secretion of a single-gene-encoded immunoglobulin from myeloma cells. Proceedings of the National Academy of Sciences of the United States of America 90, 7995-9. **(Exhibit 135)**
	136	Thanavala, Y.M. et al.
		A surrogate hepatitis B virus antigenic epitope represented by a synthetic peptide and an internal image antiidiotype antibody. Journal of Experimental Medicine 164, 227-236. **(Exhibit 136)**
	137	Towbin, H. et al.
		Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. Proceedings of the National Academy of Sciences of the United States of America 76, 4350-4. **(Exhibit 137)**
	138	Tur, M.K. et al.
		Selection of scFv phages on intact cells under low pH conditions leads to a significant loss of insert-free phages. Biotechniques 30, 404-413. **(Exhibit 138)**
	139	Umana, P. et al.
		Engineered glycoforms of an antineuroblastoma IgG1 with optimized antibody-dependent cellular cytotoxic activity. Nature Biotechnology 17, 176-180. **(Exhibit 139)**
	140	Wagner, U. et al.
		Immunological responses to the tumor-associated antigen CA125 in patients with advanced ovarian cancer induced by the murine monoclonal anti-idiotype vaccine ACA125. Hybridoma 16, 33-40. **(Exhibit 140)**
	141	Wang, B. et al.
		Human single-chain Fv immunoconjugates targeted to a melanoma-associated chondroitin sulfate proteoglycan mediate specific lysis of human melanoma cells by natural killer cells and complement. Proceedings of the National Academy of Sciences of the United States of America 96, 1627-32. **(Exhibit 141)**

	142	Watters, J.M. et al.
		An optimized method for cell-based phage display panning. Immunotechnology 3, 21-9. **(Exhibit 142)**
	143	Winter, G. et al.
		Man-made antibodies. Nature 349, 293-299. **(Exhibit 143)**
	144	Wright, A. et al.
		Effect of glycosylation on antibody function: implications for genetic engineering. Trends in Biotechnology 15, 26-31. **(Exhibit 144)**
	145	Wu, A.M. et al.
		Tumor localization of anti-CEA single-chain Fvs: improved targeting by non-covalent dimers. Immunotechnology 2, 21-36. **(Exhibit 145)**
	146	Stancovski, I. et al.
		Targeting of T lymphocytes to Neu/HERe-expressing cells using chimeric single chain Fv receptors. J Immunol, *151:* 6577-6582, 1993. **(Exhibit 146)**
	147	Moritz, D. et al.
		Cytotoxic T lymphocytes with a grafted recognition specificity for ERBB2-expressing tumor cells. Proc. Natl Acad Sci, USA, *91:* 4318-4322, 1994. **(Exhibit 147)**
	148	Wels, W. et al.
		Biotechnological and gene therapeutic strategies in cancer treatment. Gene, *159:* 73-80, 1995. **(Exhibit 148)**
	149	Eshhar, Z. et al.
		Functional expression of chimeric receptor genes in human T cells. J Immunol Methods, *248:* 67-76, 2001. **(Exhibit 149)**
	150	Wei, M. X. et al.
		Experimental tumor therapy in mice using the cyclophosphamide-activating cytochrome P450 2B1 gene. Hum Gene Ther, *5:* 969, 1994. **(Exhibit 150)**
	151	Weijtens, M. E. et al.
		Single chain Ig/gamma gene-redirected human T lymphocytes produce cytokines, specifically lyse tumor cells, and recycle lytic capacity. J Immunol, *157:* 836-843, 1996. **(Exhibit 151)**
	152	Finney, H. M. et al.
		Chimeric receptors providing both primary and costimulatory signaling in T cells from a single gene product. J Immunol, *161:* 2791-2797, 1998. **(Exhibit 152)**
	153	Koehne, G. et al.
		Rapid selection of antigen-specific T lymphocytes by retroviral transduction. Blood, *96:* 109-117, 2000. **(Exhibit 153)**

	154	Bunnell, B. A. et al.
		High-efficiency retroviral-mediated gene transfer into human nonhuman primate peripheral blood lymphocytes. Proceeds of the National Academy of Science,USA, *92:* 7739-7743, 1995. **(Exhibit 154)**
	155	Miller, A. D. et al.
		Construction and properties of retrovirus packaging cells based on gibbon ape leukemia virus. J Virol, *1991:* 2220-2224, 1991. **(Exhibit 155)**
	156	Lam, J. S. et al.
		Improved gene transfer into human lymphocytes using retroviruses with gibbon ape leukemia virus envelope. Hum Gene Ther, *7:* 1415-1422, 1996. **(Exhibit 156)**
	157	Bonini, C. et al.
		HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia. Science, *276:* 1719-1723, 1997. **(Exhibit 157)**
	158	Pollok, K. E. et al.
		High-efficiency gene transfer into normal and adenosine deaminase-deficient T lymphocytes is mediated by transduction on recombinant fibronectin fragments. J Virol, *72:* 4882-4892, 1998. **(Exhibit 158)**
	159	Galea-Lauri, J. et al.
		Expression of a variant of CD28 on a subpopulation of human NK cells: implications for B7-mediated stimulation of NK cells. J Immunol, *163:* 62-70, 1999. **(Exhibit 159)**
	160	Patel, S. D. et al.
		Impact of chimeric immune receptor extracellular protein domains on T cell function. Gene Therapy, *6:* 412-419, 1999. **(Exhibit 160)**
	161	Fitzer-Attas, C. J. et al.
		Harnessing Syk familytyrosine kinases as signaling domains for chimeric single chain of the variable domain receptors: optional design for T cell activation. J Immunol, *160:* 145-154, 1998. **(Exhibit 161)**
	162	Varez-Vallina, L. et al.
		Efficient discrimination between different densities of target antigen by tetracycline-regulatable T bodies. Hum Gene Ther, *10:* 559-563, 1999. **(Exhibit 162)**
	163	Yee, C. et al.
		In vivo tracking of tumor-specific T cells. Curr Opin Immunol, *13:* 141-146, 2001. **(Exhibit 163)**
	164	Xiaoning, R. T. et al.
		Rapid death of adoptively transferred T cells in acquired immunodeficiency syndrome. Blood, *93:* 1506-1510, 1999. **(Exhibit 164)**

	165	Riddell, S. R. et al. T-cell mediated rejection of gene-modified HIV-specific cytotoxic T lymphocytes in HIV-infected patients. Nat Med, *2:* 216-223, 1996. **(Exhibit 165)**
	166	Crist W et al. The Third Intergroup Rhabdomyosarcoma Study J Clin Oncol 13:610-30, 1995 **(Exhibit 166)**
	167	Maurer HM et al. The Intergroup Rhabdomyosarcoma Study-II. Cancer 71:1904-22, 1993 **(Exhibit 167)**
	168	Weigel BJ et al. Role of high-dose chemotherapy with hematopoietic stem cell rescue in the treatment of metastatic or recurrent rhabdomyosarcoma. J Pediatr Hematol Oncol 23:272-276, 2001 **(Exhibit 168)**
	169	Kramer K et al. Targeted radioimmunotherapy for leptomeningeal cancer using (131)I-3F8. Med Pediatr Oncol 35:716-8, 2000 **(Exhibit 169)**
	170	Kumar S et al. Myogenin is a specific marker for rhabdomyosarcoma: an immunohistochemical study in paraffin embedded tissues. Mod Pathol 13: 988-93, 2000 **(Exhibit 170)**
	171	Gattenloehner S et al. The fetal form of the acetylcholine receptor distinguishes rhabdomyosarcomas from other childhood tumors. Am J Pathol. 152:437-44, 1998 **(Exhibit 171)**
	172	Truong LD et al. A study of 584 cases and review of the literature Am J Clin Pathol 93:305-14, 1990 **(Exhibit 172)**
	173	Qualman SJ et al. Intergroup Rhabdomyosarcoma Study: update for pathologists Pediatr Dev Pathol 1:550-61, 1998 **(Exhibit 173)**
	174	Strother DR et al. Expression of the 5.1 H11 antigen, a fetal muscle surface antigen, in normal and neoplastic tissue. Arch Pathol Lab Med 114:593-596, 1990 **(Exhibit 174)**
	175	Merino ME et al. Immunomagnetic purging of ewing's sarcoma from blood and bone marrow: quantitation by real-time polymerase chain reaction. J Clin Oncol 19:3649-3659, 2001 **(Exhibit 175)**

EXAMINER	**DATE CONSIDERED**

***EXAMINER:** Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.